|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
|
NHLBI-MDS
|
The National Myelodysplatic Syndromes (MDS) Study |
Open |
|
NCI9706
|
Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy |
Open |
|
UW16004
|
Phase Ib Trial of Pembrolizumab in Combination with Dinaciclib in Subject with hematologic Malignancies |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Not Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621E
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
UW14108
|
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (CCTL019A2205B) |
Open |
|
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
|
UW15106
|
Genomic analysis of long-term survivors with metastatic cancer |
Open |
|
EAI141
|
Early Assessment of Treatment Response in AML using FLT PET/CT Imaging |
Open |
|
AALL08B1
|
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
|
Open |
|
UW16144
|
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW14113
|
A pilot study to assess engraftment using CliniMACS TCR-alpha/beta and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic progenitor cell transplantation in patients with relapsed lymphoma |
Open |
|
BMTCTN1301
|
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease |
Open |
|
S1612
|
A Randomized Phase II/III Trial of "Novel Therapeutics: Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older |
Open (affiliates only) |
|
UW16057
|
A Pilot Randomized Control Trial of a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplant |
Open |
|
AAML1331
|
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid |
Open |
|
E1910
|
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults |
Open |
|
UW17102
|
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
|
Open |
|
NCI9782
|
A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors |
Open |
|
UW18001
|
A Multicenter, Open Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated with Cancer
|
Open |
|
BMTCTN1506
|
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy following Allogeneic Transplant for Patients with FLT3/ITD AML |
Open |
UW Carbone
